TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01515488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-initiated triage
Description: Nurse-assisted triage for obtaining medical history and presenting problem(s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-triage kiosk
Description: Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
Study: NCT04682249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Chemotherapy
Description: Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib
Study: NCT00557323

Intervention type: DRUG
Intervention: Lanthanum carbonate
Study: NCT02566876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixture of three Bifidobacteria
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mixture of three Bifidobacteria
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
Study: NCT03383068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose 100 MG
Description: for metformin uneffective subjects, using acarbose for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: for metformin uneffective subjects, using Exenatide for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: for metformin uneffective subjects, using Orlistatfor 3 months

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: metformin effective subjects,act as control group
Study: NCT01619813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Reolysin and Prednisone
Description: Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and Prednisone
Description: Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
Study: NCT00688623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 5 mg tablets were supplied in blister packs
Study: NCT00058188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium gluconate
Description: Given orally
Study: NCT01089062

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: 1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: 1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: 1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
Study: NCT00058188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study: NCT02394990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Violence Brief Intervention
Description: Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABI
Study: NCT00611767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
Study: NCT03289052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Volyme
Description: Subcutis injection
Study: NCT04308954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]flumazenil
Description: \[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]flumazenil
Description: \[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
Study: NCT03466671

Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo

Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo

Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo

Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo

Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo

Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo

Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo

Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo
Study: NCT03561168

Intervention type: DIAGNOSTIC_TEST
Intervention: Change in plan of care based on MRI results
Description: Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results.

Intervention type: DIAGNOSTIC_TEST
Intervention: Change in plan of care based on MRI results
Description: Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results.

Intervention type: DIAGNOSTIC_TEST
Intervention: Change in plan of care based on MRI results
Description: Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results.
Study: NCT02323308

Intervention type: OTHER
Intervention: blood sampling
Study: NCT04825249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional suture bridge technique
Description: (A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified suture bridge technique
Description: (A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
Study: NCT01493934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of 6-DIG
Description: Unique injection dose of 92.5 MBq

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of 6-DIG
Description: Unique injection dose of 92.5 MBq
Study: NCT02985489

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olimel Parenteral Nutrition
Description: Olimel 5.7% with electrolytes
Study: NCT00063388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
Study: NCT02621645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early selective reduction of TRAP mass
Description: Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late selective reduction of TRAP mass
Description: Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
Study: NCT01089062

Intervention type: DRUG
Group type: OTHER
Intervention: IV Placebo (Saline)
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: IV Placebo (Saline)
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: IV Placebo (Saline)
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
Study: NCT02621645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle
Study: NCT01089062

Intervention type: DRUG
Group type: OTHER
Intervention: IV Placebo (Saline)
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
Study: NCT02621645

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber
Study: NCT01744041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Interpersonal Psychotherapy
Description: This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
Study: NCT00610207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)
Description: Surgical placement of the Surgisis AFP is performed under general anesthesia
Study: NCT02017457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion
Description: On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~* Patients with a sibling donor will receive:~* 5x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6~* Patients with an unrelated donor will receive:~* 1x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: * Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~* Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped.
Study: NCT02465489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone extended release
Description: Deferiprone 1000 mg extended release tablet formulation
Study: NCT01089062

Intervention type: DRUG
Group type: OTHER
Intervention: IV Placebo (Saline)
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: IV Placebo (Saline)
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Inhaler
Description: Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Inhaler
Description: Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
Study: NCT02465489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone extended release
Description: Deferiprone 1000 mg extended release tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone extended release
Description: Deferiprone 1000 mg extended release tablet formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone immediate release
Description: Ferriprox (deferiprone) 500 mg immediate release tablet formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone immediate release
Description: Ferriprox (deferiprone) 500 mg immediate release tablet formulation
Study: NCT04364906

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery
Study: NCT02572804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Catheters
Description: Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
Study: NCT03003130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Intradermal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Intradermal injection
Study: NCT01089062

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Inhaler
Description: Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
Study: NCT02382965

Intervention type: DEVICE
Intervention: transcranial focused ultrasound
Study: NCT02885272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo standard of care MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans
Study: NCT01379729

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of encapsulated beta cells.
Description: Implantation of a therapeutical dose of encapsulated beta cells.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of encapsulated beta cells.
Description: Implantation of a therapeutical dose of encapsulated beta cells.
Study: NCT03342404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Subcutaneous, every 21 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: Best Supportive Care (BSC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: Best Supportive Care (BSC)
Study: NCT05031104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: The control group received a standard exercise program for 40 minutes, three times a week for three successive months. The program encompassed aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise plus Low-energy Laser Therapy
Description: The LLT group received the same program in addition to the application of LLT on both knees, each session before exercises.
Study: NCT00625040

Intervention type: OTHER
Intervention: Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate
Description: OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test.
Study: NCT01353183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy or rectosigmoidoscopy
Description: Usual procedure
Study: NCT03712215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: diaphragmatic electrical stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: diaphragmatic electrical stimulation
Study: NCT01201967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative care
Description: Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
Study: NCT01201967

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patient's primary medical physician informed of mental health symptoms/diagnosis
Study: NCT01089062

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Inhaler
Description: Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Inhaler
Description: Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: IV Dihydroergotamine Mesylate (DHE)
Description: IV DHE administered in Treatment A as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: IV Dihydroergotamine Mesylate (DHE)
Description: IV DHE administered in Treatment A as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: IV Dihydroergotamine Mesylate (DHE)
Description: IV DHE administered in Treatment A as per protocol
Study: NCT01985386

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GDS capsule with meal
Description: GDS capsule with meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate with meal
Description: Ferrous sulfate with meal
Study: NCT01089062

Intervention type: DRUG
Group type: OTHER
Intervention: IV Dihydroergotamine Mesylate (DHE)
Description: IV DHE administered in Treatment A as per protocol
Study: NCT03628677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Study: NCT01089062

Intervention type: DRUG
Group type: OTHER
Intervention: IV Dihydroergotamine Mesylate (DHE)
Description: IV DHE administered in Treatment A as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: IV Dihydroergotamine Mesylate (DHE)
Description: IV DHE administered in Treatment A as per protocol